ASTRAZENECA COMPLETES ACQUISITION
OF TAKEDA'S RESPIRATORY BUSINESS
AstraZeneca today announced that it has completed the acquisition of the core
respiratory business of Takeda Pharmaceutical Company Limited ("Takeda"). The
agreement, announced in December 2015, (https://www.astrazeneca.com/media
-centre/press-releases/2015/AstraZeneca-to-strengthen-therapy-area-franchise
-through-acquisition-of-Takedas-respiratory-business-16122015.html) includes the
expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in
other countries), the only approved oral PDE4 inhibitor for the treatment of
chronic obstructive pulmonary disease. AstraZeneca has marketed Daliresp in the
US since the acquisition of the rights from Actavis in the first quarter of
2015.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three main therapy areas -
respiratory, inflammation, autoimmune disease (RIA), cardiovascular and
metabolic disease (CVMD) and oncology - as well as in infection and
neuroscience. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com
CONTACTS
Media Enquiries
Neil Burrows UK/Global +44 20 7604 8032
Vanessa Rhodes UK/Global +44 20 7604 8037
Karen Birmingham UK/Global +44 20 7604 8120
Jacob Lund Sweden +46 8 553 260 20
Abigail Bozarth US +1 302 885 2677
Investor Enquiries
UK
Thomas Kudsk Larsen +44 7818 524185
Eugenia Litz RIA +44 7884 735627
Nick Stone CVMD +44 7717 618834
Craig Marks Finance +44 7881 615764
Christer Gruvris Consensus Forecasts +44 7827 836825
US
Lindsey Trickett Oncology, ING +1 240 543 7970
Mitch Chan Oncology +1 240 477 3771
Dial / Toll-Free +1 866 381 7277
Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and
Metabolic Disease,
ING - Infection, Neuroscience and Gastrointestinal
03 May 2016
-ENDS-
AZ COMPLETES ACQUISITION OF TAKEDA RESPIRATORY
| Source: AstraZeneca PLC
Attachments
